Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C2H5O3S2.Na |
| Molecular Weight | 164.179 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[O-]S(=O)(=O)CCS
InChI
InChIKey=XOGTZOOQQBDUSI-UHFFFAOYSA-M
InChI=1S/C2H6O3S2.Na/c3-7(4,5)2-1-6;/h6H,1-2H2,(H,3,4,5);/q;+1/p-1
DescriptionCurator's Comment: description was created based on several sources, including:
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c79a07d-32cc-4fe7-9a74-152c169f1c4f
http://www.drugbank.ca/drugs/DB09110
https://en.wikipedia.org/wiki/Mesna
Curator's Comment: description was created based on several sources, including:
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c79a07d-32cc-4fe7-9a74-152c169f1c4f
http://www.drugbank.ca/drugs/DB09110
https://en.wikipedia.org/wiki/Mesna
Mesna is an organosulfur compound used as an adjuvant in cancer chemotherapy involving cyclophosphamide and ifosfamide. No clinical drug interaction studies have been conducted with mesna. Mesna concentrates in the bladder where acrolein accumulates after administration of chemotherapy and through a Michael addition, forms a conjugate with acrolein and other urotoxic metabolites. This conjugation reaction inactivates the urotoxic compounds to harmless metabolites. The most common adverse reactions (> 10%) when MESNEX is given with ifosfamide are nausea, vomiting, constipation, leukopenia, fatigue, fever, anorexia, thrombocytopenia, anemia, granulocytopenia, diarrhea, asthenia, abdominal pain, headache, alopecia, and somnolence.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL721: Aerolein |
|||
Target ID: CHEMBL733: 4-Hydroxyifosfamide |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Secondary | MESNEX Approved UseMesna Injection is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. Limitation of Use: Mesna Injection is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia. Mesna Injection is a cytoprotective agent indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. (1) Limitation of Use: Mesna Injection is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia. (1) Launch Date1988 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
33 μM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8462128 |
1.2 g single, oral dose: 1.2 g route of administration: Oral experiment type: SINGLE co-administered: |
MESNA blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
511 μM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8462128 |
1.2 g single, intravenous dose: 1.2 g route of administration: Intravenous experiment type: SINGLE co-administered: |
MESNA blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
79 μM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/9469350 |
0.24 g/m² single, intravenous dose: 0.24 g/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
MESNA blood | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
110 μM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8462128 |
1.2 g single, oral dose: 1.2 g route of administration: Oral experiment type: SINGLE co-administered: |
MESNA blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
201 μM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8462128 |
1.2 g single, intravenous dose: 1.2 g route of administration: Intravenous experiment type: SINGLE co-administered: |
MESNA blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
49 μM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/9469350 |
0.24 g/m² single, intravenous dose: 0.24 g/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
MESNA blood | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
92 min EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/9469350 |
0.24 g/m² single, intravenous dose: 0.24 g/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
MESNA blood | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Other AEs: Headache, Hypoaesthesia... Other AEs: Headache (43.8%) Sources: Hypoaesthesia (0%) Malaise (0%) Myalgia (0%) Nausea (0%) Pharyngitis (0%) Somnolence (6.3%) Upper respiratory infection (0%) Vomiting (0%) Dizziness (6.3%) Abdominal pain (6.3%) Coughing (0%) Diarrhea (6.3%) Anorexia (0%) Flushing (12.5%) Injection site reaction (12.5%) Back pain (6.3%) Dyspepsia (12.5%) Paraesthesia (6.3%) Renal pain (6.3%) Rigors (12.5%) Fatigue (0%) Conjunctivitis (6.3%) Arthralgia (12.5%) Application site reaction (31.3%) Photophobia (18.8%) Dehydration (6.3%) Dysuria (6.3%) Sweating increased (6.3%) |
2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Other AEs: Headache, Hypoaesthesia... Other AEs: Headache (33.3%) Sources: Hypoaesthesia (0%) Malaise (8.3%) Myalgia (0%) Nausea (16.7%) Pharyngitis (0%) Somnolence (8.3%) Upper respiratory infection (0%) Vomiting (16.7%) Dizziness (8.3%) Abdominal pain (8.3%) Coughing (0%) Diarrhea (0%) Anorexia (8.3%) Flushing (0%) Injection site reaction (0%) Back pain (0%) Dyspepsia (0%) Paraesthesia (8.3%) Renal pain (0%) Rigors (0%) Fatigue (8.3%) Conjunctivitis (0%) Arthralgia (0%) Application site reaction (0%) Photophobia (0%) Dehydration (0%) Dysuria (0%) Sweating increased (0%) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Anorexia | 0% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
| Coughing | 0% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
| Fatigue | 0% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
| Hypoaesthesia | 0% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
| Malaise | 0% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
| Myalgia | 0% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
| Nausea | 0% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
| Pharyngitis | 0% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
| Upper respiratory infection | 0% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
| Vomiting | 0% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
| Arthralgia | 12.5% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
| Dyspepsia | 12.5% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
| Flushing | 12.5% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
| Injection site reaction | 12.5% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
| Rigors | 12.5% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
| Photophobia | 18.8% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
| Application site reaction | 31.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
| Headache | 43.8% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
| Abdominal pain | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
| Back pain | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
| Conjunctivitis | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
| Dehydration | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
| Diarrhea | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
| Dizziness | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
| Dysuria | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
| Paraesthesia | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
| Renal pain | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
| Somnolence | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
| Sweating increased | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
| Application site reaction | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
| Arthralgia | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
| Back pain | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
| Conjunctivitis | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
| Coughing | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
| Dehydration | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
| Diarrhea | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
| Dyspepsia | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
| Dysuria | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
| Flushing | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
| Hypoaesthesia | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
| Injection site reaction | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
| Myalgia | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
| Pharyngitis | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
| Photophobia | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
| Renal pain | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
| Rigors | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
| Sweating increased | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
| Upper respiratory infection | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
| Nausea | 16.7% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
| Vomiting | 16.7% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
| Headache | 33.3% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
| Abdominal pain | 8.3% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
| Anorexia | 8.3% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
| Dizziness | 8.3% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
| Fatigue | 8.3% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
| Malaise | 8.3% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
| Paraesthesia | 8.3% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
| Somnolence | 8.3% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma. | 1980 Sep 27 |
|
| Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds. | 1981 |
|
| Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment. | 1982 |
|
| Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer. | 1983 Feb |
|
| Prevention of urinary bladder tumors in cyclophosphamide-treated rats by additional medication with the uroprotectors sodium 2-mercaptoethane sulfonate (mesna) and disodium 2,2'-dithio-bis-ethane sulfonate (dimesna). | 1983 Feb 15 |
|
| Prevention of cyclophosphamide-induced carcinogenesis in the urinary bladder of rats by administration of mesna. | 1983 Sep |
|
| Experience with mesna in patients receiving allogeneic bone marrow transplants for poor prognostic leukaemia. | 1983 Sep |
|
| Comparison of mesna with forced diuresis to prevent cyclophosphamide induced haemorrhagic cystitis in marrow transplantation: a prospective randomised study. | 1984 Dec |
|
| The use of sodium 2-mercaptoethane sulfonate to prevent cyclophosphamide cystitis. | 1984 May |
|
| [Prevention of tumor formation in the bladder by sodium-2-mercaptoethane sulfonate (mesna). Experimental studies and clinical consequences]. | 1984 Sep |
|
| Prevention of cyclophosphamide cystitis with 2-mercaptoethane sodium sulfonate: a histologic study. | 1984 Sep |
|
| Encephalopathy associated with ifosphamide/mesna therapy. | 1985 Feb 16 |
|
| Ifosfamide, mesna, and encephalopathy. | 1985 Jun 15 |
|
| Ifosfamide/mesa and encephalopathy. | 1985 Mar 30 |
|
| Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. | 1985 May |
|
| Cause and prevention of mafosfamide-induced venous pain. | 1986 |
|
| Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma. | 1986 |
|
| CNS-side effects induced by Ifosfamide-Mesna in children with osteosarcomas. | 1986 |
|
| Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna. | 1986 Aug |
|
| Avoiding ifosfamide/mesna encephalopathy. | 1986 Aug 16 |
|
| Prediction of ifosfamide/mesna associated encephalopathy. | 1986 Jul |
|
| The protective effect of 2-mercapto-ethane sulfonate (MESNA) on hemorrhagic cystitis induced by high-dose ifosfamide treatment tested by a randomized crossover trial. | 1986 Jun |
|
| Phase II study of ifosfamide in cervical cancer. | 1986 Jun |
|
| Blurring of vision due to ifosfamide. | 1987 |
|
| Ifosfamide/mesna encephalopathy. | 1987 Apr 25 |
|
| Irreversible encephalopathy with ifosfamide/mesna. | 1987 Aug |
|
| Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. | 1987 Aug |
|
| Ifosfamide-induced subclinical tubular nephrotoxicity despite mesna. | 1987 Feb |
|
| Encephalopathy with rapid infusion ifosfamide/mesna. | 1987 Feb 14 |
|
| Ifosfamide neurotoxicity in children. | 1987 Mar |
|
| The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. | 1987 May |
|
| Efficacy of mesna in preventing further cyclophosphamide-induced hemorrhagic cystitis. | 1988 |
|
| Ifosfamide/mesna related encephalopathy: a case report with a possible role of phenobarbital in enhancing neurotoxicity. | 1988 |
|
| [Encephalopathy caused by an ifosfamide-mesna combination]. | 1988 Apr 2 |
|
| Treatment of gynecological adenocarcinomas with a combination of ifosfamide, adriamycin and cisplatin. | 1988 May |
|
| Ifosfamide and mesna in the treatment of malignant disease mesna as urothelial protector. | 1989 Jul |
|
| Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide. An experimental study/short communication. | 1989 Jun |
|
| Encephalopathy with hyponatremia and inappropriate arginine vasopressin secretion following an intravenous ifosfamide infusion. | 1990 |
|
| Ifosfamide with mesna uroprotection in the management of lung cancer. | 1990 Apr |
|
| [Epileptic seizures and treatment with ifosfamide-mesna]. | 1994 |
|
| [Ifosfamide-induced hemorrhagic cystitis and its prevention by mesna]. | 1995 Jun |
|
| [The prevention of hemorrhagic cystitis during the performance of bone marrow and peripheral blood stem cell transplantation in the hematologic cancer clinic]. | 1996 |
|
| Ifosfamide encephalopathy and methylene-blue: a case report. | 1996 Aug |
|
| Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis. | 1996 Jun |
|
| Combined intravenous and oral mesna in outpatients treated with ifosfamide. | 1997 |
|
| Influence of mesna on urotoxic effects of selected bromosubstituted analogs of ifosfamide. | 1997 |
|
| Acrolein and chloroacetaldehyde: an examination of the cell and cell-free biomarkers of toxicity. | 2013 Feb 25 |
|
| Surface functionalities of gold nanoparticles impact embryonic gene expression responses. | 2013 Mar |
|
| Comparision of uroprotective activity of reduced glutathione with mesna in ifosfamide induced hemorrhagic cystitis in rats. | 2014 Jan-Feb |
|
| The cytogenetic action of ifosfamide, mesna, and their combination on peripheral rabbit lymphocytes: an in vivo/in vitro cytogenetic study. | 2014 Oct |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
24887
Created by
admin on Sat Dec 16 18:03:26 GMT 2023 , Edited by admin on Sat Dec 16 18:03:26 GMT 2023
|
||
|
NDF-RT |
N0000180854
Created by
admin on Sat Dec 16 18:03:26 GMT 2023 , Edited by admin on Sat Dec 16 18:03:26 GMT 2023
|
||
|
NCI_THESAURUS |
C2082
Created by
admin on Sat Dec 16 18:03:26 GMT 2023 , Edited by admin on Sat Dec 16 18:03:26 GMT 2023
|
||
|
LIVERTOX |
606
Created by
admin on Sat Dec 16 18:03:26 GMT 2023 , Edited by admin on Sat Dec 16 18:03:26 GMT 2023
|
||
|
WHO-VATC |
QR05CB05
Created by
admin on Sat Dec 16 18:03:26 GMT 2023 , Edited by admin on Sat Dec 16 18:03:26 GMT 2023
|
||
|
WHO-VATC |
QV03AF01
Created by
admin on Sat Dec 16 18:03:26 GMT 2023 , Edited by admin on Sat Dec 16 18:03:26 GMT 2023
|
||
|
WHO-ATC |
V03AF01
Created by
admin on Sat Dec 16 18:03:26 GMT 2023 , Edited by admin on Sat Dec 16 18:03:26 GMT 2023
|
||
|
FDA ORPHAN DRUG |
8685
Created by
admin on Sat Dec 16 18:03:26 GMT 2023 , Edited by admin on Sat Dec 16 18:03:26 GMT 2023
|
||
|
WHO-ATC |
R05CB05
Created by
admin on Sat Dec 16 18:03:26 GMT 2023 , Edited by admin on Sat Dec 16 18:03:26 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
8.2
Created by
admin on Sat Dec 16 18:03:26 GMT 2023 , Edited by admin on Sat Dec 16 18:03:26 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID1020809
Created by
admin on Sat Dec 16 18:03:26 GMT 2023 , Edited by admin on Sat Dec 16 18:03:26 GMT 2023
|
PRIMARY | |||
|
m7249
Created by
admin on Sat Dec 16 18:03:26 GMT 2023 , Edited by admin on Sat Dec 16 18:03:26 GMT 2023
|
PRIMARY | Merck Index | ||
|
1392807
Created by
admin on Sat Dec 16 18:03:26 GMT 2023 , Edited by admin on Sat Dec 16 18:03:26 GMT 2023
|
PRIMARY | |||
|
C192
Created by
admin on Sat Dec 16 18:03:26 GMT 2023 , Edited by admin on Sat Dec 16 18:03:26 GMT 2023
|
PRIMARY | |||
|
243-285-9
Created by
admin on Sat Dec 16 18:03:26 GMT 2023 , Edited by admin on Sat Dec 16 18:03:26 GMT 2023
|
PRIMARY | |||
|
2813
Created by
admin on Sat Dec 16 18:03:26 GMT 2023 , Edited by admin on Sat Dec 16 18:03:26 GMT 2023
|
PRIMARY | |||
|
D015080
Created by
admin on Sat Dec 16 18:03:26 GMT 2023 , Edited by admin on Sat Dec 16 18:03:26 GMT 2023
|
PRIMARY | |||
|
17905
Created by
admin on Sat Dec 16 18:03:26 GMT 2023 , Edited by admin on Sat Dec 16 18:03:26 GMT 2023
|
PRIMARY | |||
|
MESNA
Created by
admin on Sat Dec 16 18:03:26 GMT 2023 , Edited by admin on Sat Dec 16 18:03:26 GMT 2023
|
PRIMARY | |||
|
23662354
Created by
admin on Sat Dec 16 18:03:26 GMT 2023 , Edited by admin on Sat Dec 16 18:03:26 GMT 2023
|
PRIMARY | |||
|
CHEMBL1098319
Created by
admin on Sat Dec 16 18:03:26 GMT 2023 , Edited by admin on Sat Dec 16 18:03:26 GMT 2023
|
PRIMARY | |||
|
NR7O1405Q9
Created by
admin on Sat Dec 16 18:03:26 GMT 2023 , Edited by admin on Sat Dec 16 18:03:26 GMT 2023
|
PRIMARY | |||
|
SUB08784MIG
Created by
admin on Sat Dec 16 18:03:26 GMT 2023 , Edited by admin on Sat Dec 16 18:03:26 GMT 2023
|
PRIMARY | |||
|
1711
Created by
admin on Sat Dec 16 18:03:26 GMT 2023 , Edited by admin on Sat Dec 16 18:03:26 GMT 2023
|
PRIMARY | |||
|
100000092488
Created by
admin on Sat Dec 16 18:03:26 GMT 2023 , Edited by admin on Sat Dec 16 18:03:26 GMT 2023
|
PRIMARY | |||
|
44
Created by
admin on Sat Dec 16 18:03:26 GMT 2023 , Edited by admin on Sat Dec 16 18:03:26 GMT 2023
|
PRIMARY | RxNorm | ||
|
BB-59
Created by
admin on Sat Dec 16 18:03:26 GMT 2023 , Edited by admin on Sat Dec 16 18:03:26 GMT 2023
|
PRIMARY | |||
|
DB09110
Created by
admin on Sat Dec 16 18:03:26 GMT 2023 , Edited by admin on Sat Dec 16 18:03:26 GMT 2023
|
PRIMARY | |||
|
113891
Created by
admin on Sat Dec 16 18:03:26 GMT 2023 , Edited by admin on Sat Dec 16 18:03:26 GMT 2023
|
PRIMARY | |||
|
19767-45-4
Created by
admin on Sat Dec 16 18:03:26 GMT 2023 , Edited by admin on Sat Dec 16 18:03:26 GMT 2023
|
PRIMARY | |||
|
NR7O1405Q9
Created by
admin on Sat Dec 16 18:03:26 GMT 2023 , Edited by admin on Sat Dec 16 18:03:26 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
